Up to 56% reduction in WOMAC pain scores from baseline1

Clinical data chart mobile view

The most common side effects were bruising, numbness, redness, tenderness on palpation, and swelling.

Study Design: Randomized, double-blind, sham-controlled, multicenter trial with a 6-month follow-up in patients with knee OA. Patients were randomized 2:1 to cryoneurolysis targeting the infrapatellar branch of the saphenous nerve (ISN) or sham treatment (N=180; 121 in active group, 59 received sham).1

Treatment with iovera° helped patients get moving1*

  • Significant improvements in physical function demonstrated at Day 30 (P=0.001), Day 60 (P=0.04), and Day 90 (P=0.017)
  • Significant reduction in stiffness at Day 90 (P=0.03)
Award ribbon icon

Knee pain
Clinical Practice
Guideline cite
Radnovich as a
“high quality
study”1

AAOS=American Academy of Orthopaedic Surgeons; CPG=clinical practice guidelines; ISN=infrapatellar branch of the saphenous nerve; OA=osteoarthritis; TKA= total knee arthroplasty; WOMAC=Western Ontario and McMaster Universities Osteoarthritis Index.

*iovera° therapy does not treat the underlying cause of the pain; timely remediation is necessary to address the root cause.

  • Reference:
  • 1. Radnovich R et al. Osteoarthritis Cartilage. 2017;25(8):1247-1256.

See iovera°
in action

Schedule a demo

Review the
evidence

See TKA clinical efficacy
IFU View Instructions for Use
Additional Information

Pacira Pharmaceuticals, Inc.

A subsidiary of Pacira Biosciences, Inc.

10410 Science Center Drive, Building A

San Diego, CA 92121 U.S.A

Legal Disclaimer

Zimmer Biomet acquired the iovera° business from Pacira BioSciences, Inc. on 31 Jul 2026, obtaining contractual agreement for the development, manufacture, and commercialization of iovera°.

During the transition period under the applicable Transition Services Agreement, Pacira remains the legal manufacturer for applicable iovera° products and retains the related regulatory responsibilities.

Zimmer Biomet acts as a contracted service provider, performing certain design, manufacturing, quality, and post-market activities under Pacira's quality system and oversight until the transition is complete.